Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tulavi Therapeutics, Inc. operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This matter is assigned to 1 distinct examiner and is located within 1 distinct art unit. These metrics indicate a focused prosecution effort within a single technical domain. The company does not currently have a large volume of active cases or a wide distribution of examiners. This concentration suggests a highly specialized focus for the company's current research and development filings in biotechnology.
The busiest examiner for the portfolio is ATKINSON, JOSHUA ALEXANDER, who is handling 1 pending office action. This examiner is responsible for 1 busiest examiner pending case, which is the only pending action for the company. This means that ATKINSON, JOSHUA ALEXANDER is the sole official currently reviewing the company's patent applications. The involvement of 1 distinct art unit suggests that the technical subject matter is being evaluated by 1 specialized group. This concentration allows for a consistent prosecution narrative but also creates a single point of dependency for the company's patent goals. The focus on 1 distinct examiner simplifies the tracking of examiner-specific behavior and preferences, allowing for more targeted legal responses.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
| HAGOPIAN, CASEY SHEA | 1 | 54.4% | +33.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17863251 | METHODS AND DEVICES FOR NERVE REGENERATION | HAGOPIAN, CASEY SHEA | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17863251 | METHODS AND DEVICES FOR NERVE REGENERATION | HAGOPIAN, CASEY SHEA | 23d overdue |
| 18477383 | METHODS AND COMPOSITIONS FOR THE ABLATION OF NERVES | ATKINSON, JOSHUA ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18477383 | METHODS AND COMPOSITIONS FOR THE ABLATION OF NERVES | ATKINSON, JOSHUA ALEXANDER | 1612 | §103§112DP | Final Rejection | — | Pending | Sep 28, 2023 |
| 17863251 | METHODS AND DEVICES FOR NERVE REGENERATION | HAGOPIAN, CASEY SHEA | 1617 | §103§112Other | Non-Final OA | 23d overdue | Pending | Jul 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial